0001683168-22-002246.txt : 20220331
0001683168-22-002246.hdr.sgml : 20220331
20220331195105
ACCESSION NUMBER: 0001683168-22-002246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220330
FILED AS OF DATE: 20220331
DATE AS OF CHANGE: 20220331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Salkind Gene
CENTRAL INDEX KEY: 0001592481
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41117
FILM NUMBER: 22795137
MAIL ADDRESS:
STREET 1: 1165 WRACK ROAD
CITY: MEADOWBROOK
STATE: PA
ZIP: 19046
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mobiquity Technologies, Inc.
CENTRAL INDEX KEY: 0001084267
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-ADVERTISING [7310]
IRS NUMBER: 113427886
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 TORRINGTON LANE
CITY: SHOREHAM
STATE: NY
ZIP: 11786
BUSINESS PHONE: 516-256-7766
MAIL ADDRESS:
STREET 1: 35 TORRINGTON LANE
CITY: SHOREHAM
STATE: NY
ZIP: 11786
FORMER COMPANY:
FORMER CONFORMED NAME: ACE MARKETING & PROMOTIONS INC
DATE OF NAME CHANGE: 19990414
4
1
ownership.xml
X0306
4
2022-03-30
0
0001084267
Mobiquity Technologies, Inc.
MOBQ
0001592481
Salkind Gene
35 TORRINGTON LANE
SHOREHAM
NY
11766
1
0
1
0
Common Stock
2022-03-30
4
C
0
1368333
1.50
A
2484354
D
Notes
1.50
2022-03-30
4
C
0
2052500
D
2019-09-13
2029-09-13
Common Stock
513125
127500
D
Warrants
4.00
2022-03-30
4
C
0
684166
A
2022-03-30
2029-09-30
CommonStock
684166
1237500
D
The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust.
After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee.
Not applicable.
The remaining unpaid convertible notes in the principal amount of $510,000 are convertible into 127,500 shares at $4.00 per share, excluding 63,750 warrants issuable upon conversion thereof as described in note 5.
1,237,500 derivative securities include the following: (i) 127,500 shares underlying $510,000 of debt, convertible at $4.00 per share (excluding 50% warrant coverage - i.e. 63,750 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (iii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iv) warrants to purchase 686,166 shares exercisable through September 30, 2029 which were issuable on March 30, 2022 as a result of the note conversion.
/s/ Gene Salkind
2022-03-31